Flaherty J T, Becker L C, Weiss J L, Brinker J A, Bulkley B H, Gerstenblith G, Kallman C H, Weisfeldt M L
J Am Coll Cardiol. 1985 Aug;6(2):434-46. doi: 10.1016/s0735-1097(85)80183-2.
A randomized prospective clinical trial compared combined treatment with intraaortic balloon pumping and intravenous nitroglycerin for 4 to 5 days with routine clinical management in 20 patients with extensive myocardium at risk for infarction as evidenced by a thallium defect score of 7.0 units or greater. No significant differences in mortality or clinical outcome were observed between the 10 patients receiving the combined treatment and the 10 receiving routine management. In 14 patients two-dimensional echocardiograms obtained 6 to 24 hours after the onset of symptoms and at follow-up 6 to 16 days later (after completion of combined intraaortic balloon pumping plus nitroglycerin therapy) were analyzed to determine whether infarct segment or noninfarct segment lengths were affected by therapy. Among these 14 patients, 5 (3 receiving the combined therapy and 2 receiving routine management) demonstrated an increase in infarct segment length of greater than 1.0 cm. Mean infarct segment length increased 0.30 +/- 0.44 cm in patients receiving the combined therapy and 0.29 +/- 0.36 cm in patients on routine management (p = NS). In contrast, noninfarct segment length increased greater than 1.0 cm (mean increase 1.20 +/- 0.39) in five of seven patients on routine management but in none of 7 patients receiving intraaortic balloon pumping plus nitroglycerin therapy (mean decrease 0.22 +/- 0.20 cm) (p less than 0.05). No significant differences were noted in left ventricular ejection fraction, as measured by gated blood pool scintigraphy, or thallium perfusion defect score in a comparison of day 1 (pretreatment) with day 4 thallium or day 7 to 14 gated blood pool scintigrams. Thus, in patients with extensive myocardium at risk, it is unlikely that a reduction in mortality or a significant improvement in myocardial perfusion or ventricular function can be obtained by early intervention with intraaortic balloon pumping in combination with nitroglycerin. Although this combined therapy failed to prevent infarct segment lengthening (infarct expansion), the combined afterload-lowering effects of intraaortic balloon pumping and nitroglycerin did appear to prevent dilation or remodeling of noninfarcted segments during the first 2 weeks after acute myocardial infarction.
一项随机前瞻性临床试验,将20例有大面积心肌梗死风险(铊缺损评分7.0单位或更高)的患者,分为两组,一组接受主动脉内气囊反搏和静脉注射硝酸甘油联合治疗4至5天,另一组接受常规临床管理。在接受联合治疗的10例患者和接受常规管理的10例患者之间,未观察到死亡率或临床结局有显著差异。对14例患者在症状发作后6至24小时以及6至16天后随访(在完成主动脉内气囊反搏加硝酸甘油联合治疗后)所获得的二维超声心动图进行分析,以确定梗死节段或非梗死节段长度是否受治疗影响。在这14例患者中,5例(3例接受联合治疗,2例接受常规管理)梗死节段长度增加超过1.0 cm。接受联合治疗的患者梗死节段平均长度增加0.30±0.44 cm,接受常规管理的患者梗死节段平均长度增加0.29±0.36 cm(p=无显著性差异)。相比之下,7例接受常规管理的患者中有5例非梗死节段长度增加超过1.0 cm(平均增加1.20±0.39),而7例接受主动脉内气囊反搏加硝酸甘油治疗的患者中无一例非梗死节段长度增加(平均减少0.22±0.20 cm)(p<0.05)。通过门控血池闪烁显像测量左心室射血分数,以及在第1天(治疗前)与第4天铊或第7至14天门控血池闪烁显像的比较中,未发现铊灌注缺损评分有显著差异。因此,对于有大面积心肌梗死风险的患者,早期采用主动脉内气囊反搏联合硝酸甘油干预,不太可能降低死亡率或显著改善心肌灌注或心室功能。虽然这种联合治疗未能防止梗死节段延长(梗死扩展),但主动脉内气囊反搏和硝酸甘油联合降低后负荷的作用,在急性心肌梗死后的前2周内,似乎确实能防止非梗死节段的扩张或重塑。